Guardian Partners’s Guardant Health GH Stock Holding History

Guardian Partners’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,000	Closed	-$743K	–	199
2025 Q4	$743K	Buy	+7,000	New	+$626K	0.06%	141

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Guardian Partners's GH Position: Q1 2026 in Review

Guardian Partners sold out of Guardant Health (GH) in Q1 2026, closing a stake of 7,000 shares — an estimated $743K sold.

Guardian Partners first reported a position in GH in Q4 2025 and held it in 1 quarter. The position peaked at $743K in Q4 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Guardian Partners reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
Guardian Partners sold 7,000 Guardant Health shares in Q1 2026, an estimated $743K.
Guardian Partners first reported a position in Guardant Health in Q4 2025 and held it in 1 quarter.
Guardian Partners's Guardant Health position peaked at $743K in Q4 2025.
481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Guardian Partners's 13F filing for Q1 2026, filed 18 May 2026.